[go: up one dir, main page]

WO2025019733A3 - Methods for treating multiple myeloma - Google Patents

Methods for treating multiple myeloma Download PDF

Info

Publication number
WO2025019733A3
WO2025019733A3 PCT/US2024/038654 US2024038654W WO2025019733A3 WO 2025019733 A3 WO2025019733 A3 WO 2025019733A3 US 2024038654 W US2024038654 W US 2024038654W WO 2025019733 A3 WO2025019733 A3 WO 2025019733A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
multiple myeloma
treating multiple
gprc5d
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/038654
Other languages
French (fr)
Other versions
WO2025019733A2 (en
Inventor
Kathleen GRAY
Marco DE GROOT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of WO2025019733A2 publication Critical patent/WO2025019733A2/en
Publication of WO2025019733A3 publication Critical patent/WO2025019733A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Embodiments of the present invention relate to methods of reducing oral toxicities, such as taste impairment, in subjects that undergo treatment with a GPRC5D- targeted therapeutic.
PCT/US2024/038654 2023-07-20 2024-07-19 Methods for treating multiple myeloma Pending WO2025019733A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363514744P 2023-07-20 2023-07-20
US63/514,744 2023-07-20

Publications (2)

Publication Number Publication Date
WO2025019733A2 WO2025019733A2 (en) 2025-01-23
WO2025019733A3 true WO2025019733A3 (en) 2025-04-03

Family

ID=94282630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/038654 Pending WO2025019733A2 (en) 2023-07-20 2024-07-19 Methods for treating multiple myeloma

Country Status (1)

Country Link
WO (1) WO2025019733A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180037651A1 (en) * 2016-07-20 2018-02-08 Janssen Pharmaceutica Nv Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
US20230074793A1 (en) * 2021-08-06 2023-03-09 Xencor, Inc. Treatment with a bispecific antibody that binds ctla4 and pd1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180037651A1 (en) * 2016-07-20 2018-02-08 Janssen Pharmaceutica Nv Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
US20230074793A1 (en) * 2021-08-06 2023-03-09 Xencor, Inc. Treatment with a bispecific antibody that binds ctla4 and pd1

Also Published As

Publication number Publication date
WO2025019733A2 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
MX2025010928A (en) Alkynyl quinazoline compounds
EP4397372A3 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
EP4523748A3 (en) Treatment of pain and vasoconstriction
WO2003037900A3 (en) Pyrazolopyrimidines
BRPI0510094A (en) use of flibanserin for premenstrual treatment and other female sexual disorders
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
IL316433A (en) 1.8 for the treatment of pain
CA3264923A1 (en) Composition for use in the treatment of fabry disease
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2021093134A9 (en) Use of group of snake nerve growth factors and snake nerve growth factor precursors in treatment of senile dementia
WO2020101790A3 (en) Methods of using a phenoxypropylamine compound to treat pain
WO2025019733A3 (en) Methods for treating multiple myeloma
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
WO2025024305A3 (en) Irak4 degraders and uses thereof
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
WO2019232203A3 (en) Methods and compositions to alleviate vascular permeability
WO2024191937A3 (en) Compositions and methods for treating, ameliorating, and/or preventing diseases and/or disorders
WO2024083925A3 (en) Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
WO2023150703A3 (en) Methods of treatment using t-type calcium channel modulators
ZA200609220B (en) Method of treating dry eye disorders and uveitis
EP4438120A3 (en) Methods for treating cln2 disease in pediatric subjects
EP4491231A3 (en) Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
WO2024011119A3 (en) Peptides targeting sodium channels to treat pain
WO2024243004A3 (en) Compositions and methods for treating traumatic brain injury

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24843999

Country of ref document: EP

Kind code of ref document: A2